A real world study evaluating the risk of non-vertebral fracture in japanese women with osteoporosis treated with raloxifene compared with alendronate

Trial Profile

A real world study evaluating the risk of non-vertebral fracture in japanese women with osteoporosis treated with raloxifene compared with alendronate

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Raloxifene (Primary) ; Alendronic acid
  • Indications Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly Japan
  • Most Recent Events

    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top